Skip to main content
SpringerLink
Log in

Oral Glycoprotein IIb/IIIa Inhibitors

Why Don’t They Work?

  • Leading Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Despite their promise as orally active potent inhibitors of platelet aggregation, the oral platelet glycoprotein IIb/IIIa inhibitors have failed to provide a reduction in late ischemic events. In fact, with five large-scale randomized trials now complete, including over 42000 patients, these agents have been associated with a surprising, yet consistent, excess in mortality. Peculiarly, this fatality risk has occurred in the absence of a commensurate increase in other ischemic end-points. While these findings have curtailed the further clinical development of this class of potent platelet inhibitors, the obvious dissociation between platelet suppression and adverse outcome requires further clarification. Multiple putative explanations for this excess in ischemic events with oral glycoprotein IIb/IIIa inhibitors have been proposed, but definitive data implicating a specific mechanism are currently not available. While the lack of concurrent aspirin may account for some of this effect, it is unlikely to fully explain the mortality excess. Potential mechanisms include partial agonist activity leading to increased expression of platelet-leukocyte adhesion molecules, sub-optimal inhibition of platelet aggregation, genetic polymorphisms, especially phospholipase A2 polymorphism, and promotion of cardiac myocyte apoptosis via activation of caspase 3. Definitive elucidation of these adverse mechanisms will be required if further clinical development of the oral platelet glycoprotein IIb/IIIa inhibitors is to be pursued.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81-106

    Google Scholar 

  2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329–39

    Article  Google Scholar 

  3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494–502

    Article  PubMed  CAS  Google Scholar 

  4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338: 1498–505

    Article  Google Scholar 

  5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488–97

    Article  Google Scholar 

  6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436–43

    Article  Google Scholar 

  7. Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet receptor inhibition in ischemic syndrome management. Lancet 1999; 354: 1757–62

    Article  PubMed  CAS  Google Scholar 

  8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956–61

    Article  Google Scholar 

  9. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96: 76–81

    Article  PubMed  CAS  Google Scholar 

  10. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997; 96: 1117–21

    Article  PubMed  CAS  Google Scholar 

  11. Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation 1996; 94: 906–10

    Article  PubMed  CAS  Google Scholar 

  12. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 1998; 98: 1268–78

    Article  PubMed  CAS  Google Scholar 

  13. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in myocardial infarction. Circulation 1998; 97: 340–9

    Article  PubMed  CAS  Google Scholar 

  14. Harrington RA, Armstrong PW, Graffagnino C, et al. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease [In Process Citation]. Circulation 2000; 102: 728–35

    Article  PubMed  CAS  Google Scholar 

  15. Akkerhuis KM, Neuhaus KL, Wilcox RG, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J 2000; 21: 2042–55

    Article  PubMed  CAS  Google Scholar 

  16. O’Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000; 342: 1316–24

    Article  PubMed  Google Scholar 

  17. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149–56

    Article  PubMed  CAS  Google Scholar 

  18. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000; 355: 337–45

    Article  Google Scholar 

  19. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001; 103: 1727-33

  20. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201–6

    Article  PubMed  CAS  Google Scholar 

  21. Heeschen C, Hamm CW. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists. Lancet 2000; 355: 330–1

    Article  PubMed  CAS  Google Scholar 

  22. Ginsberg MH, Xiaoping D, O’Toole TE, et al. Platelet integrins. Thromb Haemost 1993; 70: 87–93

    PubMed  CAS  Google Scholar 

  23. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb–IIIa. Cardiovasc Res 2000; 45: 437–46

    Article  PubMed  CAS  Google Scholar 

  24. Holmes M, Sobel BE, Cannon CP, et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome. An OPUS-TIMI 16 substudy. Am J Cardiol 2000; 85: 491–3

    Article  PubMed  CAS  Google Scholar 

  25. Du XP, Plow EF, Frelinger AL, et al. Ligands ‘activate’ integrin alpha IIb beta 3 (platelet GPIIb–IIIa). Cell 1991; 65: 409–16

    Article  PubMed  CAS  Google Scholar 

  26. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alpha IIb beta 3) inhibitors. Blood 1998; 92: 3240–9

    PubMed  CAS  Google Scholar 

  27. Gawaz M, Ruf A, Neumann FJ, et al. Effect of glycoprotein IIb–IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998; 80: 994–1001

    PubMed  CAS  Google Scholar 

  28. Kereiakes DJ. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Am Heart J 1999; 138: S39–46

    Article  PubMed  CAS  Google Scholar 

  29. Steinhubl S, Talley D, Kereiakes D, et al. A prospective multicentre study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary interventin-the GOLD study. J Am Coll Cardiol 2000; 35: 44A

    Google Scholar 

  30. Akkerhuis M, van der Zwaan C, Wilcox R, et al. Troponin-I identifies patients with unstable coronary artery disease who benefit from long-term oral glycoprotein IIb/IIIa inhibition. Circulation 1999; 100: 1–292

    Article  Google Scholar 

  31. Kastrati A, Schomig A, Seyfarth M, et al. PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99: 1005–10

    Article  PubMed  CAS  Google Scholar 

  32. Cooke G, Liu-Stratton Y, Frid D, et al. Pharmacogenomics: response to aspirin is dose, agonists and PLA dependent. J Am Coll Cardiol 2001; 37: 276A

    Article  Google Scholar 

  33. Cook SA, Poole-Wilson PA. Cardiac myocyte apoptosis. Eur Heart J 1999; 20: 1619–29

    Article  PubMed  CAS  Google Scholar 

  34. Adderley SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000; 275: 5760–6

    Article  PubMed  CAS  Google Scholar 

  35. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999; 397: 534–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, Ohio, 44195, USA

    Derek P. Chew, Deepak L. Bhatt &  Eric J. Topol

Authors
  1. Derek P. Chew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepak L. Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric J. Topol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric J. Topol.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chew, D.P., Bhatt, D.L. & Topol, E.J. Oral Glycoprotein IIb/IIIa Inhibitors. Am J Cordiovosc Drugs 1, 421–428 (2001). https://doi.org/10.2165/00129784-200101060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200101060-00002

Keywords

Search

Navigation